GlassScriptPhysician profile
Cathy C Davis
NPI 1891152906
$6,552.84
in general payments reported to CMS, 2019-2025
20 companies · $912 in 2025
The $912 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $1,673 · 2023: $1,803 · 2024: $1,399 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,420.93 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $896.75 | 2021-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $726.00 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $599.99 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $584.43 | 2022-2024 | Perseris, Sublocade |
| Teva Pharmaceuticals USA, INC. | $555.70 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $548.12 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $401.72 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $296.07 | 2021-2025 | Invega, Invega Sustenna, Spravato |
| Lundbeck LLC | $111.59 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $104.68 | 2021-2022 | |
| Axsome Therapeutics, INC. | $76.03 | 2024 | Auvelity |
| Boston Scientific Corporation | $41.85 | 2024 | Lithovue |
| Noven Therapeutics, LLC | $37.82 | 2024 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $35.41 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $28.35 | 2024-2025 | Cobenfy |
| Braeburn INC. | $28.21 | 2024 | Brixadi |
| Allergan, INC. | $23.40 | 2021 | |
| Luye Pharma (USA) LTD. | $20.79 | 2025 | Erzofri Extended-Release |
| Mckesson Medical-Surgical, INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.